Massimiliano Fabbiani

Siena, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 139 publications

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.

Journal: The Journal of antimicrobial chemotherapy

Published: December 18, 2025

Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153.

Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153.

Journal: Science translational medicine

Published: December 10, 2025

Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort.

Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort.

Journal: AIDS (London, England)

Published: October 26, 2025

Use of Tobacco and Alternative Nicotine Products Among People with HIV: A Cross-Sectional Multicenter Survey.

Use of Tobacco and Alternative Nicotine Products Among People with HIV: A Cross-Sectional Multicenter Survey.

Journal: AIDS and behavior

Published: October 25, 2025

Treatment of post-lung transplantation pneumonia with cefiderocol: a case series and insights from the literature.

Treatment of post-lung transplantation pneumonia with cefiderocol: a case series and insights from the literature.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: October 25, 2025

Durability of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Adults Living With HIV: A Multicenter Observational Cohort in Tuscany (LAHIV).

Durability of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Adults Living With HIV: A Multicenter Observational Cohort in Tuscany (LAHIV).

Journal: Journal of medical virology

Published: October 02, 2025

Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.

Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.

Journal: Journal of translational medicine

Published: August 30, 2025

Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: Epidemiology, clinical features and outcomes in the era of antimicrobial resistance.

Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: Epidemiology, clinical features and outcomes in the era of antimicrobial resistance.

Journal: Journal of global antimicrobial resistance

Published: February 08, 2025

Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study).

Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study).

Journal: The Journal of antimicrobial chemotherapy

Published: January 09, 2025

Machine learning approaches to dissect hybrid and vaccine-induced immunity.

Machine learning approaches to dissect hybrid and vaccine-induced immunity.

Journal: Communications medicine

Published: December 12, 2024

Prevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV.

Prevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV.

Journal: Diagnostics (Basel, Switzerland)

Published: December 09, 2024

Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial.

Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial.

Journal: Infectious diseases and therapy

Published: August 31, 2024

Showing 1-12 of 139

Last Updated: 09/26/2026